T. Rowe Price Investment Management, Inc. Ascendis Pharma A/S Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 3,583,546 shares of ASND stock, worth $715 Million. This represents 0.39% of its overall portfolio holdings.
Number of Shares
3,583,546
Previous 3,053,824
17.35%
Holding current value
$715 Million
Previous $476 Million
29.95%
% of portfolio
0.39%
Previous 0.31%
Shares
12 transactions
Others Institutions Holding ASND
# of Institutions
276Shares Held
60MCall Options Held
217KPut Options Held
73.3K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.05 Billion38.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$1.09 Billion4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.98MShares$994 Million15.67% of portfolio
-
Janus Henderson Group PLC London, X04.43MShares$884 Million0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$850 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.1B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...